ZAI LAB LIMITED Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ZAI LAB LIMITED share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 20.26M shares, a 293.65% increase from fiscal 2024.
- ZAI LAB LIMITED share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 5.15M shares, a 21.02% decline from fiscal 2023.
- ZAI LAB LIMITED share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 6.52M shares, a 26.51% increase from fiscal 2022.
- ZAI LAB LIMITED share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 5.15M shares, a 316.99% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2025-12-31 | 20.26M shares 10-K · filed 2026-02-26 | |
| 2024-12-31 | 5.15M shares 10-K · filed 2025-02-27 | |
| 2023-12-31 | 6.52M shares 10-K · filed 2024-02-27 | |
| 2022-12-31 | 5.15M shares 10-K · filed 2023-03-01 | |
| 2021-12-31 | 1.24M shares 10-K · filed 2022-03-01 | |
| 2020-12-31 | 899.36K shares 10-K · filed 2021-03-01 | |
| 2019-12-31 | 670.94K shares 10-K · filed 2021-03-01 | |
| 2018-12-31 | 256.06K shares 10-K · filed 2021-03-01 | |
| 2017-12-31 | 100.83K shares 20-F · filed 2020-04-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |